Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Preclinical studies for pharmacokinetics and biodistribution of AD-stTRAIL, an adenovirus delivering secretable trimeric trail for gene therapy

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Kim, C. Y.
  • Park, S. H.
  • Jeong, M.
  • Kwon, O. S.
  • Doh, H.
  • Kang, S. H.
  • Robbins, Paul D.
  • Kim, B. M.
  • Seol, D. W.
  • Kim, B. G.

publication date

  • October 2011

journal

  • Experimental and Molecular Medicine  Journal

abstract

  • Malignant glioma is the most frequent type in brain tumors. The prognosis of this tumor has not been significantly improved for the past decades and the average survival of patients is less than one year. Thus, an effective novel therapy is urgently needed. TNF-related apoptosis inducing ligand (TRAIL), known to have tumor cell-specific killing activity, has been investigated as a novel therapeutic for cancers. We have developed Ad-stTRAIL, an adenovirus delivering secretable trimeric TRAIL for gene therapy and demonstrated the potential to treat malignant gliomas. Currently, this Ad-stTRAIL gene therapy is under phase I clinical trial for malignant gliomas. Here, we report preclinical studies for Ad-stTRAIL carried out using rats. We delivered Ad-stTRAIL intracranially and determined its pharmacokinetics and biodistribution. Most Ad-stTRAIL remained in the delivered site and the relatively low number of viral genomes was detected in the opposite site of brain and cerebrospinal fluid. Similarly, only small portion of the viral particles injected was found in the blood plasma and major organs and tissues, probably due to the brain-blood barrier. Multiple administrations did not lead to accumulation of Ad-stTRAIL at the injection site and organs. Repeated delivery of Ad-stTRAIL did not show any serious side effects. Our data indicate that intracranially delivered Ad-stTRAIL is a safe approach, demonstrating the potential as a novel therapy for treating gliomas.

subject areas

  • Adenoviridae
  • Animals
  • Blood-Brain Barrier
  • Brain
  • Brain Neoplasms
  • Clinical Trials, Phase I as Topic
  • DNA, Viral
  • Disease Models, Animal
  • Drug Delivery Systems
  • Drug Evaluation, Preclinical
  • Genetic Therapy
  • Glioma
  • Humans
  • Liver
  • Protein Multimerization
  • Rats
  • Spleen
  • TNF-Related Apoptosis-Inducing Ligand
scroll to property group menus

Research

keywords

  • TNF-related apoptosis-inducing ligand
  • gene therapy
  • glioma
  • pharmacokinetics
scroll to property group menus

Identity

PubMed Central ID

  • PMC3222819

International Standard Serial Number (ISSN)

  • 1226-3613

Digital Object Identifier (DOI)

  • 10.3858/emm.2011.43.10.065

PubMed ID

  • 21822049
scroll to property group menus

Additional Document Info

start page

  • 580

end page

  • 586

volume

  • 43

issue

  • 10

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support